Previous 10 | Next 10 |
2023-05-10 11:34:08 ET Vericel Corporation (VCEL) Q1 2023 Earnings Conference Call May 10, 2023, 8:30 AM ET Company Participants Eric Burns - Vice President, Finance and Investor Relations Nick Colangelo - President and CEO Joe Mara - Chief Financial Officer ...
2023-05-10 07:57:23 ET Vericel press release ( NASDAQ: VCEL ): Q1 GAAP EPS of -$0.16 misses by $0.01 . Revenue of $41.01M (+13.7% Y/Y) beats by $3.64M . Full-Year 2023 Revenue Guidance Raised to $184-$192 Million vs $186.54M consensus For further...
Record First Quarter Total Revenue of $41 Million MACI Revenue Increased 32% to $34.2 Million Full-Year 2023 Revenue Guidance Raised to $184-$192 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Vericel Corpora...
2023-05-09 11:25:33 ET Vericel ( NASDAQ: VCEL ) is scheduled to announce Q1 earnings results on Wednesday, May 10th, before market open. The consensus EPS Estimate is -$0.16 and the consensus Revenue Estimate is $37.37M (+3.6% Y/Y). Over the last 1 year, VCEL has bea...
Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor PR Newswire CHICAGO , May 2, 2023 /PRNewswire/ -- Dimension Inx, a biomaterials platform company developing therapeutics ...
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its first-quarter 2023 financial results on Wednesday, May 10, 2023. Vericel’s ma...
2023-04-02 09:14:27 ET Summary The FDA's recent approval of NexoBrid for the treatment of burns is expected to drive revenue growth in 2023. Vericel's MACI autologous cell therapy product for knee cartilage defects is on track for a potential accelerated commercial launch in 2024....
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the Canaccord Genuity Musculoskeletal Conference. The ...
Vericel Corporation (VCEL) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET Company Participants Eric Burns – Head-Financial Planning and Analysis and Investor Relations. Nick Colangelo – President and Chief Executive Officer Joe Mara –...
The following slide deck was published by Vericel Corporation in conjunction with their 2022 Q4 earnings call. For further details see: Vericel Corporation 2022 Q4 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Karen Mahoney as Chief Human Resources Officer following the retirement of Heidi Hassen, w...
CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2024 financial results on Thursday, August 1, 2024. Vericel’s m...
2024-07-08 00:00:04 ET Ryan Zimmerman from BTIG issued a price target of $56.00 for VCEL on 2024-07-05 10:09:00. The adjusted price target was set to $56.00. At the time of the announcement, VCEL was trading at $46.68. The overall price target consensus is at $48.00 with...